Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Editor's Pick Epidemiology and Surveillance

Patients at Risk for Aortic Rupture Often Exposed to Fluoroquinolones during Hospitalization

William C. Frankel, Barbara W. Trautner, Andrew Spiegelman, Larissa Grigoryan, Scott A. LeMaire
William C. Frankel
aBaylor College of Medicine, Houston, Texas, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for William C. Frankel
Barbara W. Trautner
bHouston VA Center for Innovations in Quality, Effectiveness, and Safety (IQuESt), Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas, USA
cSection of Health Services Research, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA
dMichael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew Spiegelman
eAdvisory Board Company, Washington, DC, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Larissa Grigoryan
fDepartment of Family and Community Medicine, Baylor College of Medicine, Houston, Texas, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Scott A. LeMaire
gDivision of Cardiothoracic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas, USA
hDepartment of Cardiovascular Surgery, Texas Heart Institute, Houston, Texas, USA
iCardiovascular Research Institute, Baylor College of Medicine, Houston, Texas, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.01712-18
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Several studies have indicated that fluoroquinolone use may be associated with an increased risk of aortic aneurysm or dissection (AAD). Because patients with AAD or Marfan syndrome are at increased risk for aortic rupture, we performed a retrospective cohort study to determine the prevalence of systemic fluoroquinolone exposure and predictors of fluoroquinolone use in these patients. Data were obtained from the advisory board billing and administrative database, which contained information on 22 million adult hospitalizations in the United States for the study period (2009 to 2015). International Classification of Diseases (9/10) and Current Procedural Terminology codes were used to identify patients who had AAD or Marfan syndrome or underwent aortic repair. We identified 136,789 admissions for AAD, which involved 99,818 unique patients, 20% of whom received fluoroquinolone during a hospital admission. Of the 7,045 patients with dissection, 18% were exposed to fluoroquinolone. Of the 27,876 AAD patients who underwent aortic repair, 19% received fluoroquinolone during a hospitalization before the repair. In the AAD patients, having a diagnosis of pneumonia or urinary tract infection increased the likelihood of receiving fluoroquinolone during admission by 46% and 40%, respectively (P < 0.001). Additionally, we identified 2,871 admissions for Marfan syndrome, which involved 1,872 patients, 14% of whom received fluoroquinolone during an admission. In these patients, pneumonia and urinary tract infections also increased the risk of fluoroquinolone exposure. If the deleterious effects of fluoroquinolone on aortic integrity are substantiated, reducing fluoroquinolone use in hospitalized patients with aortic disorders will become an urgent safety issue for antibiotic stewardship programs.

INTRODUCTION

Aortic aneurysms are characterized by weakening and subsequent focal dilation of the aortic wall. Often, aortic aneurysms cause no symptoms until they rupture, a catastrophic event associated with an estimated mortality rate of over 80% (1). In addition, patients with an aortic aneurysm are at risk of developing aortic dissection, which is characterized by separation of the layers of the aorta. Aortic dissection also has a grave prognosis because it commonly results in rupture (2, 3). The literature on risk factors associated with aortic aneurysm and/or dissection (AAD) is robust. The main nonmodifiable risk factors associated with AAD development are older age, male sex (men have a 4-fold increased risk compared with women), and family history of aortic disease, whereas the strongest modifiable risk factor is smoking (4). Another well-described risk factor for AAD development is Marfan syndrome, which is a genetic disorder caused by an inherited mutation in the gene for fibrillin, resulting in abnormal connective tissue. An estimated one-third of patients with Marfan syndrome have an aortic event during their lifetime (5). Given the devastating effect of aortic disease, it is critical to avoid factors that promote aortic damage, disease progression, and eventual aortic dissection or rupture when managing patients at high risk for AAD (6, 7).

Fluoroquinolones (FQs) are among the most commonly prescribed antibiotics worldwide (8–10). They are used to treat a variety of common bacterial infections, including urinary tract infections (UTIs) (11–14) and pneumonia (15, 16). Fluoroquinolones are also used to treat infected aortic aneurysms (17–19). Postmarketing surveillance and clinical studies have indicated that FQs are associated with several adverse effects (20), including tendonitis and tendon rupture (21–23), QT prolongation (24), dysglycemia (25, 26), and neuropathy (27–30). Because of the adverse effects associated with FQ use, the United States Food and Drug Administration (FDA) issued a black box warning for FQs in 2016 and has provided updated warnings several times since then (31–33). Moreover, FQ use is one of the factors that has led to the recent emergence and global dissemination of the multidrug-resistant Escherichia coli strain sequence type 131 (34), and FQ exposure puts patients at high risk of subsequently developing a Clostridium difficile infection (35).

Recently, the results of 4 observational clinical studies have suggested that FQ use may also be associated with an increased risk of AAD (36–39). Although the underlying mechanisms have yet to be fully determined, this alarming association has raised concern that AAD patients may progress to aortic rupture while being treated with FQs. In a recent laboratory-based study, we found that exposure to the FQ ciprofloxacin increased the incidence of aortic dissection and rupture in a mouse model of AAD (40), further substantiating that caution should be used when considering the use of FQ in patients who have aortic dilatation or are otherwise at high risk for AAD. In response to this additional evidence, the European Medicines Agency (EMA) Pharmacovigilance Risk Assessment Committee released an official warning against the use of FQ in patients with diagnosed AAD or conditions that predispose an individual to aneurysm development (41).

In light of these escalating concerns, we decided to explore how often patients with AAD or Marfan syndrome are actually receiving FQ antibiotics, given that these patients are at increased risk of aortic rupture. In this retrospective cohort study, we examined the prevalence of FQ exposure in patients with AAD or Marfan syndrome in the acute care setting. Our secondary aim was to determine the clinical and demographic factors most predictive of FQ exposure in these patients, with the eventual goal of targeting antibiotic stewardship interventions to the patients most at risk.

This work was presented, in part, at the Society for Healthcare Epidemiology of America 2018 spring meeting, 20 April 2018 in Portland, Oregon.

RESULTS

Demographics.For this study, we analyzed hospital admissions data from the advisory board billing and administrative database for the years 2009 to 2015. Using this database, we identified 134,469 unique admissions for AAD, which involved 99,818 unique patients (Table 1). Six percent of these admissions (n = 8,035) were for dissection. We also identified 2,871 unique admissions for Marfan syndrome, which involved 1,872 unique patients. Of these, 338 had AAD and, thus, were also included in the AAD group. For the AAD admissions, the patients were predominantly male (67%). As expected, for the Marfan syndrome admissions, the patients were younger, were more likely to be female, had a lower comorbidity index, were less likely to smoke, and were less likely to be admitted for a UTI or chronic obstructive pulmonary disease than those admitted for AAD (P < 0.001 for all comparisons).

View this table:
  • View inline
  • View popup
TABLE 1

Characteristics of the cohorts studieda

Fluoroquinolone exposure.Of the 99,818 patients with AAD, 19,889 (20%) were administered an FQ antibiotic during a hospital admission (Table 2). For the subset of 7,045 patients with dissection, the proportion exposed to FQ was 18%. For the AAD patients who underwent aortic repair, the overall FQ exposure was 12% (3,301/27,806), which was significantly lower than the 20% exposure for the entire AAD group (P < 0.001). Furthermore, for the AAD patients who underwent aortic repair, the proportion exposed to FQ was significantly higher before the repair than during or after the repair (19% versus 11%, P < 0.001). Concerningly, 23% of the patients with diagnosed AAD who did not undergo repair were exposed to FQ during a hospitalization; this exposure was significantly higher than the 12% for the aortic repair patients (P < 0.001). For the Marfan syndrome patients, the proportion exposed to FQ was 14%; the exposure proportions did not differ significantly among the Marfan patients who did or did not have AAD (P = 0.75), did or did not have dissection (P = 0.78), or did or did not undergo repair (P = 0.13).

View this table:
  • View inline
  • View popup
TABLE 2

Fluoroquinolone exposure during hospital admission in patients at risk for aortic rupture

Predictors of fluoroquinolone exposure for patients with AAD.A multilevel logistic regression analysis revealed that several clinical factors were predictive of FQ use in the patients with AAD (Table 3). Factors found to be independently associated with a higher likelihood of FQ use included having a diagnosis of pneumonia (odds ratio [OR], 6.22; 95% confidence interval [CI], 2.32 to 16.69) and having a diagnosis of UTI (OR, 4.97; 95% CI, 2.09 to 11.82). In the patients with AAD, having a diagnosis of pneumonia or urinary tract infection increased the likelihood of receiving FQ during an admission by 46% and 40%, respectively (P < 0.001). Factors associated with being less likely to receive FQ during an admission included being male (OR, 0.79; 95% CI, 0.70 to 0.90) and undergoing aortic repair (OR, 0.62; 95% CI 0.48 to 0.80). Of the two-way interactions between variables that were assessed, only “pneumonia × UTI” achieved statistical significance. Although pneumonia and UTIs were both associated with an increased likelihood of FQ exposure, having both did not have an additive effect. Rather, the patients with both pneumonia and a UTI had only a slightly greater chance of FQ exposure than patients with only pneumonia.

View this table:
  • View inline
  • View popup
TABLE 3

Predictors of exposure to fluoroquinolones in patients with aortic aneurysm and/or dissectiona

Predictors of fluoroquinolone exposure for patients with Marfan syndrome.A multilevel logistic regression analysis revealed that a narrower set of clinical factors were predictive of FQ use in the patients with Marfan syndrome (Table 4). Factors independently associated with a higher likelihood of FQ use included having a diagnosis of pneumonia (OR, 10.53; 95% CI 6.57 to 16.87) and having a diagnosis of UTI (OR, 7.90; 95% CI, 4.99 to 12.52).

View this table:
  • View inline
  • View popup
TABLE 4

Predictors of exposure to fluoroquinolones in patients with Marfan syndromea

DISCUSSION

Given the grave prognoses associated with aortic rupture, it is important to reduce the modifiable risk factors associated with the development or progression of AAD. In the present study, we found that 20% of the patients with diagnosed AAD, 19% of the patients hospitalized before aortic repair, and 14% of the patients with diagnosed Marfan syndrome were exposed to FQ during a hospital admission. For both the AAD patients and the Marfan syndrome patients, a diagnosis of UTI or pneumonia was associated with an increased risk of FQ exposure during hospitalization. Therefore, a substantial proportion of patients with AAD were exposed to FQ while in the hospital, and having infections that are commonly treated with FQ increased the risk of exposure.

Because of the risks described as being associated with FQ use, there has been a decrease in FQ use in recent years; however, FQs remain the most commonly prescribed class of antibiotics in inpatient and outpatient settings (42, 43). Fluoroquinolones are frequently prescribed for the treatment of UTIs (43) and are a key component of the empirical treatment of community-acquired pneumonia (15, 16). Consistent with this, we found that one-fifth of the patients with AAD received FQ, particularly if the patient also had pneumonia or a UTI.

Our finding that having pneumonia or a UTI increased the likelihood of FQ exposure in both AAD and Marfan syndrome patients is not surprising given the frequency with which FQ drugs are used (appropriately or inappropriately) for these indications. We also found that within the group of patients with AAD, women were more likely to receive a FQ antibiotic than men. A possible explanation for this finding is that women are more likely to be diagnosed with and treated for a UTI during hospitalization (44). The lower risk of FQ exposure in hospitalizations that occurred during or after aortic repair than in those that occurred before repair may reflect a shorter time available to be hospitalized after repair in this population comprising mostly older adults. We observed the inverse relationship in the population of Marfan syndrome patients (i.e., more patients were exposed to FQs during hospitalizations that occurred after repair).

All database studies, including ours, have limitations that must be considered when interpreting the results. Although it would be of interest to examine FQ exposure in separate aneurysm and dissection cohorts, this was not possible because of limitations related to coding practices that precluded reliable identification of patients who had aneurysm without dissection or who had dissection without aneurysm. In our analyses, we were unable to include admissions or repair procedures that occurred at hospitals not reporting to the advisory board billing and administrative database. The database did not contain any information about the indications for antibiotic use or why a specific antibiotic was chosen, so we cannot specify the prescribers’ motives for the increased use of FQ in women and decreased use in Marfan syndrome patients. Furthermore, we were unable to determine the prevalence of FQ exposure during hospital admissions involving the general population, preventing us from including this comparison group. Our results only show the incidence of FQ exposure in the inpatient setting. Because FQs are frequently prescribed in the outpatient setting (10, 45), our results very likely underestimate the overall incidence of exposure to these drugs in patients with AAD and Marfan syndrome. The purpose of our study was to describe the frequency of FQ exposure in patients with AAD, but the results do not imply a causal relationship. There is still an immediate need for additional translational research to expand our understanding of the biologic mechanisms underlying the association between the use of FQ antibiotics and the occurrence of adverse aortic events.

Our study revealed that a large number of patients with AAD, including those with unrepaired lesions, are receiving FQ antibiotics. If the suspected deleterious effect of FQs on aortic integrity is substantiated, reducing FQ use in these patients should be a high priority for antibiotic stewardship and patient safety programs. Our results help identify the patients who are most at risk of FQ exposure during hospitalization and, thus, provide a starting place for stewardship interventions.

MATERIALS AND METHODS

Data sources and study population.The protocol was reviewed by the Baylor College of Medicine institutional review board. The board determined that this project did not constitute human subjects research. The data were gathered from the advisory board billing and administrative database, a comprehensive reporting system that collects data from acute-care hospitals across the United States. For the years 2009 through 2015, the database included patient-specific data on 22 million hospitalizations involving adults. The database provides a cross-payer perspective; it includes hospital billing and administrative data for inpatient and outpatient encounters covered by commercial insurance, government insurance, self-pay, and charity care. The data in the database were deidentified in accordance with the Health Insurance Portability and Accountability Act (HIPAA) privacy rule. The hospitals contributing to this database are generally representative of hospitals across the United States, except that there are fewer small facilities (i.e., <50 beds) and fewer facilities in the western United States; these differences were ≤5% from the national averages determined by the American Hospital Association. We have used this database for prior studies of antibiotic use (43, 46).

Measures.To create a cohort of patients at risk for aortic rupture, we used International Classification of Diseases (ICD-9/10) codes to identify records regarding patients with an aortic aneurysm (thoracic or abdominal), an aortic dissection, or Marfan syndrome or who underwent aortic repair (see Table S1 in the supplemental material). We also used Current Procedural Terminology (CPT) codes to determine if a procedure had been performed. We included patients with a diagnosis of AAD or Marfan syndrome anywhere among the admission diagnoses. We included patients with ruptured aneurysm because those who undergo surgical repair of the ruptured segment (especially those with a ruptured thoracic aorta) often have other unrepaired segments with disease that remain at risk for progression. We also identified the following diagnoses among the admission diagnoses by using ICD-9/10 codes: pneumonia, UTI, emphysema, and chronic obstructive pulmonary disease (see Table S1). These additional diagnoses were studied because they are the leading causes of antibiotic use in inpatient hospitalizations. We focused on admission diagnoses in order to capture data regarding the clinical scenario that will need to be addressed by antibiotic stewardship interventions if FQ is proven to increase risk in patients with AAD. Stewardship programs will need to identify all patients with a primary or secondary diagnosis of AAD at the time of admission and discourage prescription of FQ in such patients. Patient demographic data extracted from the database included sex, age (continuous), length of stay (continuous), tobacco use (yes or no), and Elixhauser score. Aortic repair procedures were identified by using both CPT and ICD-9/10 codes.

Fluoroquinolone exposure was defined as any instance of a systemic FQ being ordered during a hospitalization, including when such medications were given in the emergency department on the first day of admission. We queried the Charge Description Master codes for the names of all the FQ drugs approved in the United States (ciprofloxacin, gatifloxacin, levofloxacin, moxifloxacin, ofloxacin, and their corresponding brand names) to determine which patients were exposed to FQ during their hospital admission. Topical, otic, and ophthalmic formulations of FQ were excluded from the list. Complete details of the codes used to generate our cohort are included in the supplemental materials (Table S1). We identified 2 patient groups, namely the AAD group, which included all patients who had an aneurysm and/or dissection involving the thoracic or abdominal aorta and were 18 years old or older; and the Marfan syndrome group, which included all patients with Marfan syndrome, regardless of their age or whether they had an aneurysm or dissection. Marfan syndrome patients with AAD were included in the AAD group and the Marfan syndrome group for analyses. Because dissection patients are at particularly high risk for rapid aortic expansion and rupture, we also identified a subgroup of the AAD group that comprised adult patients with confirmed aortic dissection (rather than aneurysm without dissection). Because of the inherent limitations of the coding structure, we were not able to reliably identify patients with dissection who did not have aneurysm or vice versa. Patients who had a length of stay over 31 days were excluded to ensure that our study focused on acute, inpatient hospitalizations. Each patient could have had multiple admissions.

Statistical analysis.First, we identified all the AAD admissions and the Marfan syndrome admissions separately using the corresponding ICD-9/10 codes. Then, we separated our cohort of patients with AAD on the basis of more granular diagnoses (i.e., thoracic AAD, abdominal AAD, dissection, Marfan syndrome, and aortic repair procedures). Next, for the patients fitting each diagnostic profile, we determined what percentage of the patients was exposed to FQs. Summary statistics were compared by using the chi-square test, Kruskal-Wallis test, Wilcoxon-Mann-Whitney test, 2-sample proportion test, or independent sample t test, depending on the nature of the variables.

Because of the hierarchical nature of the data, we used multilevel logistic regression to analyze the predictive value of various admission characteristics on FQ use in both the AAD group and the Marfan syndrome group. We have used this approach in prior studies to examine the effects of urine culture at admission on antibiotic selection (46). The levels were facilities and attending physicians, which means we accounted for clustering of observations by facility and attending level. To mitigate the problem of multiple comparisons and ensure model parsimony, we chose the predictors of our statistical model not through one regression but through repeated bootstrapped samples. This procedure mitigates multiple comparison problems by insisting on predictor significance across many random samples. The model for all AAD patients was developed by using repeated random samples of 30,000 until the model’s estimates were stable. With each sample, we noted which predictors influenced the model (P < 0.25) and excluded predictors that had a P value of ≥0.25 in the previous step. The predictors evaluated were sex, age, length of stay, aortic repair, pneumonia, UTI, aneurysm, dissection, Elixhauser score, tobacco use, diagnosis of emphysema, diagnosis of chronic obstructive pulmonary disease, diagnosis of Marfan syndrome, and all two-way interactions (such as pneumonia and UTI). We repeated the procedure 50 times. Because each random sample was large (n = 30,000), there was no substantive statistical power lost compared with using the full data set. Because effects are not uniform over all values of a predictor in logistic regression, we included maximum effect estimates in addition to traditional odds ratios. The same analysis was performed with the Marfan syndrome group by using repeated random samples of 1,000. All analyses were performed in R 3.4. (R Core Team 2017) (47).

ACKNOWLEDGMENTS

B.W.T. was supported by the Center for Innovations in Quality, Effectiveness and Safety (CIN 13-413) at the Michael E. DeBakey VA Medical Center, Houston, TX. S.A.L. was supported, in part, by the Jimmy and Roberta Howell Professorship in Cardiovascular Surgery at Baylor College of Medicine.

We declare no conflicts of interest with the contents of this article.

FOOTNOTES

    • Received 14 August 2018.
    • Returned for modification 5 September 2018.
    • Accepted 20 November 2018.
    • Accepted manuscript posted online 26 November 2018.
  • Supplemental material for this article may be found at https://doi.org/10.1128/AAC.01712-18.

  • Copyright © 2019 American Society for Microbiology.

All Rights Reserved.

REFERENCES

  1. 1.↵
    1. Reimerink JJ,
    2. van der Laan MJ,
    3. Koelemay MJ,
    4. Balm R,
    5. Legemate DA
    . 2013. Systematic review and meta-analysis of population-based mortality from ruptured abdominal aortic aneurysm. Br J Surg 100:1405–1413. doi:10.1002/bjs.9235.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Nienaber CA,
    2. Clough RE
    . 2015. Management of acute aortic dissection. Lancet 385:800–811. doi:10.1016/S0140-6736(14)61005-9.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Pape LA,
    2. Awais M,
    3. Woznicki EM,
    4. Suzuki T,
    5. Trimarchi S,
    6. Evangelista A,
    7. Myrmel T,
    8. Larsen M,
    9. Harris KM,
    10. Greason K,
    11. Di Eusanio M,
    12. Bossone E,
    13. Montgomery DG,
    14. Eagle KA,
    15. Nienaber CA,
    16. Isselbacher EM,
    17. O'Gara P
    . 2015. Presentation, diagnosis, and outcomes of acute aortic dissection: 17-year trends from the international registry of acute aortic dissection. J Am Coll Cardiol 66:350–358. doi:10.1016/j.jacc.2015.05.029.
    OpenUrlFREE Full Text
  4. 4.↵
    1. Kent KC,
    2. Zwolak RM,
    3. Egorova NN,
    4. Riles TS,
    5. Manganaro A,
    6. Moskowitz AJ,
    7. Gelijns AC,
    8. Greco G
    . 2010. Analysis of risk factors for abdominal aortic aneurysm in a cohort of more than 3 million individuals. J Vasc Surg 52:539–548. doi:10.1016/j.jvs.2010.05.090.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    1. Groth KA,
    2. Stochholm K,
    3. Hove H,
    4. Kyhl K,
    5. Gregersen PA,
    6. Vejlstrup N,
    7. Ostergaard JR,
    8. Gravholt CH,
    9. Andersen NH
    . 2017. Aortic events in a nationwide Marfan syndrome cohort. Clin Res Cardiol 106:105–112. doi:10.1007/s00392-016-1028-3.
    OpenUrlCrossRef
  6. 6.↵
    1. Herrington W,
    2. Lacey B,
    3. Sherliker P,
    4. Armitage J,
    5. Lewington S
    . 2016. Epidemiology of atherosclerosis and the potential to reduce the global burden of atherothrombotic disease. Circ Res 118:535–546. doi:10.1161/CIRCRESAHA.115.307611.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Yoon SS,
    2. Carroll MD,
    3. Fryar CD
    . 2015. Hypertension prevalence and control among adults: United States, 2011–2014. NCHS Data Brief 1–8.
  8. 8.↵
    1. Linder JA,
    2. Huang ES,
    3. Steinman MA,
    4. Gonzales R,
    5. Stafford RS
    . 2005. Fluoroquinolone prescribing in the United States: 1995 to 2002. Am J Med 118:259–268. doi:10.1016/j.amjmed.2004.09.015.
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    1. Mamdani M,
    2. McNeely D,
    3. Evans G,
    4. Hux J,
    5. Oh P,
    6. Forde N,
    7. Conly J
    . 2007. Impact of a fluoroquinolone restriction policy in an elderly population. Am J Med 120:893–900. doi:10.1016/j.amjmed.2007.02.028.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Zhang Y,
    2. Steinman MA,
    3. Kaplan CM
    . 2012. Geographic variation in outpatient antibiotic prescribing among older adults. Arch Intern Med 172:1465–1471. doi:10.1001/archinternmed.2012.3717.
    OpenUrlCrossRefPubMedWeb of Science
  11. 11.↵
    1. Grigoryan L,
    2. Trautner BW,
    3. Gupta K
    . 2014. Diagnosis and management of urinary tract infections in the outpatient setting: a review. JAMA 312:1677–1684. doi:10.1001/jama.2014.12842.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Hooton TM,
    2. Bradley SF,
    3. Cardenas DD,
    4. Colgan R,
    5. Geerlings SE,
    6. Rice JC,
    7. Saint S,
    8. Schaeffer AJ,
    9. Tambayh PA,
    10. Tenke P,
    11. Nicolle LE
    . 2010. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. Clin Infect Dis 50:625–663. doi:10.1086/650482.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    1. Matthews SJ,
    2. Lancaster JW
    . 2011. Urinary tract infections in the elderly population. Am J Geriatr Pharmacother 9:286–309. doi:10.1016/j.amjopharm.2011.07.002.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Mehnert-Kay SA
    . 2005. Diagnosis and management of uncomplicated urinary tract infections. Am Fam Physician 72:451–456.
    OpenUrlPubMedWeb of Science
  15. 15.↵
    1. Mandell LA,
    2. Wunderink RG,
    3. Anzueto A,
    4. Bartlett JG,
    5. Campbell GD,
    6. Dean NC,
    7. Dowell SF,
    8. File TM, Jr,
    9. Musher DM,
    10. Niederman MS,
    11. Torres A,
    12. Whitney CG
    , Infectious Diseases Society of America, American Thoracic Society. 2007. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44:S27–S72. doi:10.1086/511159.
    OpenUrlCrossRefPubMedWeb of Science
  16. 16.↵
    1. Woodhead M,
    2. Blasi F,
    3. Ewig S,
    4. Garau J,
    5. Huchon G,
    6. Ieven M,
    7. Ortqvist A,
    8. Schaberg T,
    9. Torres A,
    10. van der Heijden G,
    11. Read R,
    12. Verheij TJ
    , Joint Taskforce of the European Respiratory Society, European Society for Clinical Microbiology and Infectious Diseases. 2011. Guidelines for the management of adult lower respiratory tract infections–full version. Clin Microbiol Infect 17:E1–E59. doi:10.1111/j.1469-0691.2011.03602.x.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Laohapensang K,
    2. Rutherford RB,
    3. Arworn S
    . 2010. Mycotic abdominal aortic aneurysm due to Streptococcus suis: a case report. Surg Infect (Larchmt) 11:179–181. doi:10.1089/sur.2008.111.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Risse J,
    2. Settembre N,
    3. Mandry D,
    4. Benayad H,
    5. Lemarie C,
    6. Alauzet C,
    7. Zuily S,
    8. Bertaux A,
    9. Malikov S,
    10. Claudon M,
    11. Wahl D
    . 2015. Infected abdominal aortic aneurysm attributable to Haemophilus influenzae: rapid changes of imaging findings. Circulation 132:613–615. doi:10.1161/CIRCULATIONAHA.115.016323.
    OpenUrlFREE Full Text
  19. 19.↵
    1. Thompson PC,
    2. Wang L,
    3. Columbo J,
    4. Schanzer A,
    5. Robinson WP
    . 2015. Durable results with in situ graft repair of ruptured salmonella aneurysm in a patient with autoimmune deficiency syndrome. Int J Angiol 25:e131–e134. doi:10.1055/s-0035-1556840.
    OpenUrlCrossRef
  20. 20.↵
    1. Mehlhorn AJ,
    2. Brown DA
    . 2007. Safety concerns with fluoroquinolones. Ann Pharmacother 41:1859–1866. doi:10.1345/aph.1K347.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Huston KA
    . 1994. Achilles tendinitis and tendon rupture due to fluoroquinolone antibiotics. N Engl J Med 331:748. doi:10.1056/NEJM199409153311116.
    OpenUrlCrossRefPubMedWeb of Science
  22. 22.↵
    1. Stephenson AL,
    2. Wu W,
    3. Cortes D,
    4. Rochon PA
    . 2013. Tendon injury and fluoroquinolone use: a systematic review. Drug Saf 36:709–721. doi:10.1007/s40264-013-0089-8.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Wise BL,
    2. Peloquin C,
    3. Choi H,
    4. Lane NE,
    5. Zhang Y
    . 2012. Impact of age, sex, obesity, and steroid use on quinolone-associated tendon disorders. Am J Med 125:1228.e23–1228.e28. doi:10.1016/j.amjmed.2012.05.027.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Briasoulis A,
    2. Agarwal V,
    3. Pierce WJ
    . 2011. QT prolongation and torsade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications. Cardiology 120:103–110. doi:10.1159/000334441.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Aspinall SL,
    2. Good CB,
    3. Jiang R,
    4. McCarren M,
    5. Dong D,
    6. Cunningham FE
    . 2009. Severe dysglycemia with the fluoroquinolones: a class effect? Clin Infect Dis 49:402–408. doi:10.1086/600294.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Chou HW,
    2. Wang JL,
    3. Chang CH,
    4. Lee JJ,
    5. Shau WY,
    6. Lai MS
    . 2013. Risk of severe dysglycemia among diabetic patients receiving levofloxacin, ciprofloxacin, or moxifloxacin in Taiwan. Clin Infect Dis 57:971–980. doi:10.1093/cid/cit439.
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Ali AK
    . 2014. Peripheral neuropathy and Guillain-Barre syndrome risks associated with exposure to systemic fluoroquinolones: a pharmacovigilance analysis. Ann Epidemiol 24:279–285. doi:10.1016/j.annepidem.2013.12.009.
    OpenUrlCrossRef
  28. 28.↵
    1. Aoun M,
    2. Jacquy C,
    3. Debusscher L,
    4. Bron D,
    5. Lehert M,
    6. Noel P,
    7. van der Auwera P
    . 1992. Peripheral neuropathy associated with fluoroquinolones. Lancet 340:127. doi:10.1016/0140-6736(92)90460-K.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Cohen JS
    . 2001. Peripheral neuropathy associated with fluoroquinolones. Ann Pharmacother 35:1540–1547. doi:10.1345/aph.1Z429.
    OpenUrlCrossRefPubMedWeb of Science
  30. 30.↵
    1. Etminan M,
    2. Brophy JM,
    3. Samii A
    . 2014. Oral fluoroquinolone use and risk of peripheral neuropathy: a pharmacoepidemiologic study. Neurology 83:1261–1263. doi:10.1212/WNL.0000000000000846.
    OpenUrlCrossRefPubMed
  31. 31.↵
    US Food and Drug Administration. 2016. FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects. Silver Spring, MD: US Food and Drug Administration. https://www.fda.gov/downloads/Drugs/DrugSafety/UCM513019.pdf.
  32. 32.↵
    US Food and Drug Administration. 2016. FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections; warns about disabling side effects that can occur together. U.S. Food and Drug Administration, Silver Spring, MD. https://www.fda.gov/downloads/Drugs/DrugSafety/UCM500591.pdf.
  33. 33.↵
    US Food and Drug Administration. 2018. FDA updates warnings for fluoroquinolone antibiotics on risks of mental health and low blood sugar adverse reactions. Silver Spring, MD: US Food and Drug Administration. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm612995.htm.
  34. 34.↵
    1. Petty NK,
    2. Ben Zakour NL,
    3. Stanton-Cook M,
    4. Skippington E,
    5. Totsika M,
    6. Forde BM,
    7. Phan MD,
    8. Gomes Moriel D,
    9. Peters KM,
    10. Davies M,
    11. Rogers BA,
    12. Dougan G,
    13. Rodriguez-Bano J,
    14. Pascual A,
    15. Pitout JD,
    16. Upton M,
    17. Paterson DL,
    18. Walsh TR,
    19. Schembri MA,
    20. Beatson SA
    . 2014. Global dissemination of a multidrug resistant Escherichia coli clone. Proc Natl Acad Sci U S A 111:5694–5699. doi:10.1073/pnas.1322678111.
    OpenUrlAbstract/FREE Full Text
  35. 35.↵
    1. Pepin J,
    2. Saheb N,
    3. Coulombe MA,
    4. Alary ME,
    5. Corriveau MP,
    6. Authier S,
    7. Leblanc M,
    8. Rivard G,
    9. Bettez M,
    10. Primeau V,
    11. Nguyen M,
    12. Jacob CE,
    13. Lanthier L
    . 2005. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 41:1254–1260. doi:10.1086/496986.
    OpenUrlCrossRefPubMedWeb of Science
  36. 36.↵
    1. Daneman N,
    2. Lu H,
    3. Redelmeier DA
    . 2015. Fluoroquinolones and collagen associated severe adverse events: a longitudinal cohort study. BMJ Open 5:e010077. doi:10.1136/bmjopen-2015-010077.
    OpenUrlAbstract/FREE Full Text
  37. 37.↵
    1. Lee CC,
    2. Lee MG,
    3. Hsieh R,
    4. Porta L,
    5. Lee WC,
    6. Lee SH,
    7. Chang SS
    . 2018. Oral fluoroquinolone and the risk of aortic dissection. J Am Coll Cardiol 72:1369–1378. doi:10.1016/j.jacc.2018.06.067.
    OpenUrlFREE Full Text
  38. 38.↵
    1. Lee CC,
    2. Lee MT,
    3. Chen YS,
    4. Lee SH,
    5. Chen YS,
    6. Chen SC,
    7. Chang SC
    . 2015. Risk of aortic dissection and aortic aneurysm in patients taking oral fluoroquinolone. JAMA Intern Med 175:1839–1847. doi:10.1001/jamainternmed.2015.5389.
    OpenUrlCrossRefPubMed
  39. 39.↵
    1. Pasternak B,
    2. Inghammar M,
    3. Svanstrom H
    . 2018. Fluoroquinolone use and risk of aortic aneurysm and dissection: nationwide cohort study. BMJ 360:k678. doi:10.1136/bmj.k678.
    OpenUrlAbstract/FREE Full Text
  40. 40.↵
    1. LeMaire SA,
    2. Zhang L,
    3. Luo W,
    4. Ren P,
    5. Azares AR,
    6. Wang Y,
    7. Zhang C,
    8. Coselli JS,
    9. Shen YH
    . 2018. Effect of ciprofloxacin on susceptibility to aortic dissection and rupture in mice. JAMA Surg 153:e181804. doi:10.1001/jamasurg.2018.1804.
    OpenUrlCrossRef
  41. 41.↵
    European Medicines Agency. 2018. PRAC recommendations on signals. London, United Kingdom: European Medicines Agency. https://www.ema.europa.eu/documents/prac-recommendation/prac-recommendations-signals-adopted-3-6-september-2018-prac-meeting_en-0.pdf.
  42. 42.↵
    1. Baggs J,
    2. Fridkin SK,
    3. Pollack LA,
    4. Srinivasan A,
    5. Jernigan JA
    . 2016. Estimating national trends in inpatient antibiotic use among US hospitals from 2006 to 2012. JAMA Intern Med 176:1639–1648. doi:10.1001/jamainternmed.2016.5651.
    OpenUrlCrossRef
  43. 43.↵
    1. Kallen AJ,
    2. Welch HG,
    3. Sirovich BE
    . 2006. Current antibiotic therapy for isolated urinary tract infections in women. Arch Intern Med 166:635–639. doi:10.1001/archinte.166.6.635.
    OpenUrlCrossRefPubMedWeb of Science
  44. 44.↵
    1. Horstman MJ,
    2. Spiegelman A,
    3. Naik AD,
    4. Trautner BW
    . 2017. National patterns of urine testing during inpatient admission. Clin Infect Dis 65:1199–1205. doi:10.1093/cid/cix424.
    OpenUrlCrossRef
  45. 45.↵
    1. Kabbani S,
    2. Hersh AL,
    3. Shapiro DJ,
    4. Fleming-Dutra KE,
    5. Pavia AT,
    6. Hicks LA
    . 2018. Opportunities to improve fluoroquinolone prescribing in the United States for adult ambulatory care visits. Clin Infect Dis 67:134–136. doi:10.1093/cid/ciy035.
    OpenUrlCrossRefPubMed
  46. 46.↵
    1. Horstman MJ,
    2. Spiegelman AM,
    3. Naik AD,
    4. Trautner BW
    . 2018. Urine culture on admission impacts antibiotic use and length of stay: a retrospective cohort study. Infect Control Hosp Epidemiol 39:547–554. doi:10.1017/ice.2018.55.
    OpenUrlCrossRef
  47. 47.↵
    R Core Team. 2014. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing. http://www.R-project.org/.
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
Patients at Risk for Aortic Rupture Often Exposed to Fluoroquinolones during Hospitalization
William C. Frankel, Barbara W. Trautner, Andrew Spiegelman, Larissa Grigoryan, Scott A. LeMaire
Antimicrobial Agents and Chemotherapy Jan 2019, 63 (2) e01712-18; DOI: 10.1128/AAC.01712-18

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Patients at Risk for Aortic Rupture Often Exposed to Fluoroquinolones during Hospitalization
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Patients at Risk for Aortic Rupture Often Exposed to Fluoroquinolones during Hospitalization
William C. Frankel, Barbara W. Trautner, Andrew Spiegelman, Larissa Grigoryan, Scott A. LeMaire
Antimicrobial Agents and Chemotherapy Jan 2019, 63 (2) e01712-18; DOI: 10.1128/AAC.01712-18
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • INTRODUCTION
    • RESULTS
    • DISCUSSION
    • MATERIALS AND METHODS
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

aortic disease
fluoroquinolones

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596